Comparison of operational criteria for treatment outcome in gambiense human African trypanosomiasis

Tropical Medicine and International Health

Volumn 14, Issue 4, 2009, Pages 438-444

  Mumba Ngoyi, D ^b   Lejon, V ^a   N'Siesi, F X ^c   Boelaert, M ^a   Buscher P ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Institut National de Recherche Biomedicale   (Congo)

^c Ministry of Health   (Congo)

Author keywords

African sleeping sickness; African trypanosomiasis; Cerebrospinal fluid; Relapse; Sensitivity; Specificity; Treatment outcome; Trypanosoma brucei gambiense; White blood cell count

Indexed keywords

MELARSOPROL; NIFURTIMOX; SURAMIN;

BLOOD; CELL ORGANELLE; DATA SET; DISEASE; HEALTH CARE; INFECTIOUS DISEASE; PROTOZOAN;

AFRICAN TRYPANOSOMIASIS; ARTICLE; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HUMAN; INFECTION CONTROL; LEUKOCYTE COUNT; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; RELAPSE; TREATMENT FAILURE; TREATMENT OUTCOME; TRYPANOSOMA; TRYPANOSOMA GAMBIENSE;

ANIMALS; HUMANS; LEUKOCYTE COUNT; PREDICTIVE VALUE OF TESTS; RECURRENCE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

TRYPANOSOMA BRUCEI GAMBIENSE;

EID: 62449124514     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2009.02248.x     Document Type: Article

References (22)

1. Balasegaram M, Chappuis F, Karunakara U, Priotto G Ruiz JA (2004) Sleeping sickness. A practical manual for the treatment and control of human African tryponosomiasis. Médecins sans Frontières, Paris, pp. 1 179.
2. Balasegaram M, Harris S, Checchi F, Hamel C Karunakara U (2006) Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Bulletin of the World Health Organization 84, 777 782.
3. Bisser S, N'Siesi FX, Lejon V et al. (2007) Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. Journal of Infectious Diseases 195, 322 329.
4. Burri C, Nkunku S, Merolle A et al. (2000) Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355, 1419 1425.
5. Cattand P, Miézan BT de Raadt P (1988) Human African trypanosomiasis: use of double centrifugation of cerebrospinal fluid to detect trypanosomes. Bulletin of the World Health Organization 66, 83 86.
6. Emerson JF Emerson SS (2005) Evaluation of a standardized procedure for counting microscopic cells in body fluids. Journal of Clinical Laboratory Analysis 19, 267 275.
7. Lejon V, Robays J, N'Siesi FX et al. (2007) Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM and interleukin-10 in patients with hemo-lymphatic stage sleeping sickness. Clinical and Vaccine Immunology 14, 732 737.
8. Lejon V, Roger M, Mumba Ngoyi D et al. (2008) Novel markers for treatment outcome in late stage T.b. gambiense trypanosomiasis. Clinical Infectious Diseases 47, 15 22.
9. Lourie EM (1942) Treatment of sleeping sickness in Sierra Leone. Tropical Medicine and Parasitology 36, 113 131.
10. Milord F, Pépin J, Loko L, Ethier L Mpia B (1992) Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 340, 652 655.
11. Pépin J Milord F (1994) The treatment of human African trypanosomiasis. Advances in Parasitology 33, 2 49.
12. Pépin J, Milord F, Bokelo M et al. (1989) An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Transactions of the Royal Society of Tropical Medicine and Hygiene 83, 514 517.
13. Pépin J, Khonde N, Maiso F et al. (2000) Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bulletin of the World Health Organization 78, 1284 1295.
14. Priotto G, Fogg C, Balasegaram M et al. (2006) Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. Plos Clinical Trials 1, 1 8.
15. Priotto G, Kasparian S, Ngouma D et al. (2007) Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clinical Infectious Diseases 45, 1435 1442.
16. Priotto G, Pinoges L, Badi Fursa I et al. (2008) Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. British Medical Journal 336, 705 708.
17. Robays J, Nyamowala G, Sese C et al. (2008) High failure rates of melarsoprol of sleeping sickness, Democratic Republic of Congo. Emerging Infectious Diseases 14, 966 967.
18. Schmid C, Nkunku S, Merolle A, Vounatsou P Burri C (2004) Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 364, 789 790.
19. Van Nieuwenhove S (1999) Present strategies in the treatment of human African trypanosomiasis. In : Progress in Human African Trypanosomiasis, Sleeping Sickness (eds M Dumas, B Bouteille A Buguet) Springer, Paris, pp. 253 281.
20. WHO (1986) Epidemiology and Control of African Trypanosomiasis. WHO Technical Report Series 739, Geneva.
21. WHO (1998) Control and Surveillance of African Trypanosomiasis. WHO Technical Report Series 881, Geneva.
22. WHO (2007) Recommendations of the Informal Consultation on Issues for Clinical Product Development for Human African Trypanosomiasis. WHO/CDS/NTD/IDM/2007.1, Geneva.